Eyenovia, Inc. announced the appointment of current Chief Operating Officer Michael Rowe as the Company's new Chief Executive Officer, effective August 1, 2022. Mr. Rowe's appointment follows the company's nationwide search and interviews with multiple candidates. Mr. Rowe has also been appointed to Eyenovia's Board of Directors, increasing the Board to nine seats following recent appointments of Drs.

Strahlman and Palanki as new independent directors, announced in July. Eyenovia's current Chief Executive Officer, Dr. Sean Ianchulev, previously announced that he will be transitioning to Chairman of the company's Board. Mr. Rowe has served as the Company's Chief Operating Officer since January 2021, having first joined the Company in July 2018 as Corporate Vice President.

In his 30+ year career, Mr. Rowe spent 12 years at Allergan founding the health economics department, leading strategic planning and new pharmaceutical and device product commercialization for the global glaucoma franchise and founding the competitive intelligence function across the company. During this time, Mr. Rowe also served as the company's liaison with Senju Pharmaceuticals (a current shareholder and licensee of Eyenovia) and was instrumental in the successful launch of multiple glaucoma products in the Japanese market. More recently, Mr. Rowe was with Aerie Pharmaceuticals, Inc. where he was pivotal in the commercialization of their glaucoma franchise.

Mr. Rowe has also held leadership roles at Bayer Healthcare Pharmaceuticals Inc. and Pfizer, Inc.